Picture [LSUS] – The Business Web Portal 600x60px
Organisation › Details

Teva (Group)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. *


Period Start 1994-01-01 existent
Products Industry DRUGS, GENERICS
  Industry 2 pharmaceutical
Persons Person Levin, Jeremy (Teva 201205– before BMS since 200709 before Novartis 2003–2007 before Cadus CEO)
  Person 2 Sekhri, Paul J. (Lycera Corp 201502– CEO before Sanofi + Teva + TPG Biotech + Cerimon + Ariad + Sprout)
Region Region Petah Tikwa
  Country Israel
  Street 5 Basel St.
  City 49131 Petah Tikva
  Tel +972-3-9267267
    Address record changed: 2018-07-24
Basic data Employees H: 10,001 to 50,00 (2011-09-15)
  Currency USD
  Annual sales 21,903,000,000 (revenues, net, consolidated (2016) 2016-12-31)
  Profit 311,000,000 (2016-12-31)
  Cash 988,000,000 (2016-12-31)
    * Document for �About Section�: Teva Pharmaceutical Industries Ltd.. (8/4/16). "Press Release: Teva Reports Second Quarter 2016 Results". Jerusalem.
Record changed: 2018-10-30


Picture [LSA] – The Business Web Portal 650x89px

More documents for Teva (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top